Transfer Factor Immunotherapy in Cancer

Veito, R. Mark; Burger, Denis R.; Nolte, James E.; Vandenbark, Arthur A.

doi:10.1016/b978-0-12-064650-0.50056-8

Cited by 6 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding other metastatic cancers, patients with malignant melanoma have been most often treated with TF. Cumulative results from various series [22,[40][41][42][43][44][45][46][47] indicate an overall response rate of 16 out of 64 patients. Obviously, however, not all patients were treated in the same fashion.…”

Section: Transfer Factor Therapy In Cancermentioning

confidence: 99%

“…Obviously, however, not all patients were treated in the same fashion. For example, Krementz et al [40] transfused viable lymphocytes rather than TF in most of their patients, and some patients from other series had additional radiotherapy [43] or BCG immunization [47] along with TF. "Response" was defined variably or not at all, and was itself reported as quite variable in duration and degree.…”

Section: Transfer Factor Therapy In Cancermentioning

confidence: 99%

See 1 more Smart Citation

Transfer factor: A potential agent for immunotherapy of cancer

Meier

LoBuglio

1977

World j. surg.

View full text Add to dashboard Cite

Transfer factor (TF) is an extract from human leukocytes which has been shown to transfer specific skin test reactivity to previously nonreactive human recipients, and to produce measurable increases in in Vitro tests of lymphocyte activity. The results of the experimental use of TF as an immunotherapeutic agent for cancer are reviewed. TF therapy has been associated with tumor regression, temporary stabilization or reduced need for other treatment modalities in several reported cancer patients, and may have value as an adjuvant therapy in certain malignancies. However, most of the reports involve uncontrolled studies, and no agreement exists about the definition of TF donors. Controlled studies and the use of well characterized TF donors are essential before any conclusions can be drawn about the value of TF in the therapy of cancer and other diseases.

show abstract

Section: Transfer Factor Therapy In Cancermentioning

confidence: 99%

Section: Transfer Factor Therapy In Cancermentioning

confidence: 99%

Transfer factor: A potential agent for immunotherapy of cancer

Meier

LoBuglio

1977

World j. surg.

View full text Add to dashboard Cite

show abstract

“…Several authors have used, with discordant results, transfer factor (TF) (BULLOCK et al, 1972;CAN-DIDO SILVA at a/., 1973;FABER at al., 1979;GODAL, 1974;HASTINGS at al., 1976;LAWRENCE, 1968;SAHA et al, 1975) or total blood transfusion (ALMEIDA GONÇALVES & CUSTÓ- DIO, 1975;LIM et a/., 1972) or viable leukocytes (ANTIA & KHANOLKAR, 1974;BULLOCK at al., 1972;PARA-DISI et al, 1969;SAHA et al, 1975) in patients with the Virchow cells type (BRIEGER & ALLEN, 1964;KHA-NOLKAR, 1964) in an attempt to obtain the transfer of skin reactivity or to reactivate the immunodeficient mechanisms. The TF, as a terapeutic w e a p on , h ad i ts e ff ic ie n c y d emonstrated in several diseases with d e f i c i e n c y o f C M I ( B A S T E N e t CATANZARO & SPITLER, 1976;GRAYBILL et al, 1973;GRIS-CELLI et al, 1973;HITZIG & GROB, 1974;KIRKPATRICK & GALLIN, 1974;LAWRENCE, 1969LAWRENCE, , 1974LE-VIN et a/., 1970MEN-DES & MENDES, 1976;PABST & SWANSON, 1972;ROCKLIN, 1975;ROCKLIN et al, 1970;SCHULKIND & AYOUB, 1975;SILVA et a/., 1976;SPITLER et al, 1975;VETTO at a/., 1976).…”

Section: Introductionmentioning

confidence: 99%

Cell mediated immunity in patients with virchowian hanseniasis before and after treatment with transfer factor

LESER,

MARGARIDO,

BELDA

et al. 1980

Hansen. Int.

View full text Add to dashboard Cite

Cell mediated immunity (CMI), bacterial index (BI), morphological index (MI), skin and lymph nodes biopsies were evaluated in 15 patients with virchowian hanseniasis before and after treatment with transfer factor (TF) obtained from human spleens. The patients were divided in 3 groups: group I (control) received only sulforiti, group II received sulfone plus TF and group III received only TF. There was no difference in the numbers of peripherical T and B lymphocytes of patients and normal controls. Before the treatment with TF, there was an impaired response of the patient's peripheral lymphocytes to PHA stimulus, in the presence of autologous or homologous plasma. This depressed response was corrected after treatment With TF in the patients of group III. In none of the patients a positive Mitsuda reaction was observed before and after treatment with TF. The improvement of the MI observed in group IH, treated only with TF was remarkably similar to the patients treated only with sulfone. This work points out that TF has a role in the treatment of patients with virchowian hanseniasis, based on the improvement of CMI, MI, on histopathology of skin biopsies and clinical conditions.

show abstract

Transfer factor 1993: New frontiers

Fudenberg¹,

Pizza

1994

Progress in Drug Research / Fortschritte Der Arzneimittelforschung / Progrès Des Recherches Pharmaceutiques

View full text Add to dashboard Cite

Transfer Factor Immunotherapy in Cancer

Cited by 6 publications

References 3 publications

Transfer factor: A potential agent for immunotherapy of cancer

Transfer factor: A potential agent for immunotherapy of cancer

Cell mediated immunity in patients with virchowian hanseniasis before and after treatment with transfer factor

Transfer factor 1993: New frontiers

Contact Info

Product

Resources

About